Teva Breaks into Injectable Generics with its US$3.4 B Acquisition of SICOR

doi:10.3833/pdr.v2003i42.848

Pharma Deals Review, Vol 2003, No 42 (2003)

Teva Breaks into Injectable Generics with its US$3.4 B Acquisition of SICOR

Business Review Editor

Abstract

Teva Pharmaceutical Industries entered into an agreement to acquire SICOR for approximately US$3.4 B, which allows Teva to take advantage of the enormous growth in generic pharmaceuticals. SICOR’s generic injectable drug portfolio will strengthen Teva’s generic oral dose products.

Full Text: pdf

Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.